News und Analysen
![Antibe Therapeutics Engages Stern IR for Investor Relations Services](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support
![NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company
![Vifor Pharma Group Reports Continued Growth in H1 2020](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Vifor Pharma Group Reports Continued Growth in H1 2020
Regulatory News:
Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect
![Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Regulatory News:
Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose
![Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
![FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
![Xencor to Present at Upcoming Investor Conferences](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
![STAAR Surgical Reports Second Quarter 2020 Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
STAAR Surgical Reports Second Quarter 2020 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
![Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
“We are very excited about our global
![Hanger Reports Second Quarter 2020 Financial Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Hanger Reports Second Quarter 2020 Financial Results
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the second quarter ended June 30, 2020
![Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its
![EnWave Signs Commercial License and Equipment Purchase Agreement with Orto Al Sole to use REV™ Technology in Italy](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EnWave Signs Commercial License and Equipment Purchase Agreement with Orto Al Sole to use REV™ Technology in Italy
Vancouver, B.C., August 5, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced today
![EnWave unterzeichnet kommerziellen Lizenz- und Gerätekaufvertrag mit Orto Al Sole für Nutzung der REV™ Technologie in Italien](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
EnWave unterzeichnet kommerziellen Lizenz- und Gerätekaufvertrag mit Orto Al Sole für Nutzung der REV™ Technologie in Italien
Vancouver, B.C., 5. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
![Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational
![LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
![Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth
![Charles River Laboratories Announces Second-Quarter 2020 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Charles River Laboratories Announces Second-Quarter 2020 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6
![IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that
![True Leaf informiert über aktuellen Stand des Umstrukturierungsprozesses](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
True Leaf informiert über aktuellen Stand des Umstrukturierungsprozesses
Vernon (British Columbia), 5. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf und seine Tochtergesellschaften am 31.
![True Leaf Provides Update on Restructuring Process](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
True Leaf Provides Update on Restructuring Process
Vernon, BC - August 5, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, on July 31, 2020, True Leaf and its subsidiaries obtained Orders
![Novavax: Nachbörsliche Räuberpistole!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Novavax: Nachbörsliche Räuberpistole!
Gestern Abend kam es nachbörslich zu einer wilden Berg- und Talfahrt bei der Aktie des US-amerikanischen Biotechunternehmens Novavax (WKN: A2PKMZ). Der Grund hierfür wirkt kurios.
Zunächst einmal
![Evotec: Vorstand streckt Fühler nach Antisense-Startup aus](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Evotec: Vorstand streckt Fühler nach Antisense-Startup aus
Evotec (WKN: 566480) geht seine nächste strategische Partnerschaft ein. So wurde, wie heute vermeldet, mit dem Marburger Next-Generation-Wirkstoffforscher Secarna Pharmaceuticals eine Kooperation im
![QIAGEN Reports Full Results for Second Quarter and First Half Of 2020](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in
![Xencor Reports Second Quarter 2020 Financial Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![QIAGEN meldet vollständige Ergebnisse des zweiten Quartals und des ersten Halbjahrs 2020](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
QIAGEN meldet vollständige Ergebnisse des zweiten Quartals und des ersten Halbjahrs 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die vollständigen Ergebnisse der operativen Tätigkeit für das zweite Quartal und das erste Halbjahr 2020 bekannt, wobei der